Sept. 12 (Bloomberg) -- Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Cos. won an appeal in their bid to sell a generic version of BASF SE’s heart medicine Lovaza in the U.S.
The U.S. Court of Appeals for the Federal Circuit in a ruling today said it reversed a lower court decision because one patent held by BASF’s Pronova unit had been made publicly accessible and another had expired.
The ruling sent shares of Amarin Corp., the maker of a competing medicine, down as much as 12 percent, the biggest drop since December 2012. Teva’s American depositary receipts, rose 1.1 percent to $38.94 at 12:14 p.m. New York time.
Lovaza is the first and only fish-oil derived prescription drug approved by the U.S. Food and Drug Administration, and Petach Tikva, Israel-based Teva and Par want to market generic versions, the court said in its ruling.
U.S. sales of Lovaza were more than $2.3 billion as of August 2010, the court said.
Pronova was acquired this year by Ludwigshafen, Germany-based BASF, and Par was bought last year by TPG Capital.
To contact the reporter on this story: Todd Shields in Washington at firstname.lastname@example.org;
To contact the editor responsible for this story: Bernard Kohn at email@example.com